Regenetp (Regenetp) EBIT per Share : $-1.21 (TTM As of Mar. 2023)

View and export this data going back to 1999. Start your Free Trial

What is Regenetp EBIT per Share?

Regenetp's EBIT per Share for the three months ended in Mar. 2023 was $-0.65. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2023 was $-1.21.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Regenetp's EBIT per Share or its related term are showing as below:

RGTPQ's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.4
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Regenetp's EBIT for the three months ended in Mar. 2023 was $-4.75 Mil.

Regenetp EBIT per Share Historical Data

The historical data trend for Regenetp's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenetp EBIT per Share Chart

Regenetp Annual Data

Trend

Oct13

Oct14

Oct15

Oct16

Oct17

Oct18

Dec19

Dec20

Dec21

Dec22

EBIT per Share

Get a 7-Day Free Trial

-113.82

-93.49

-26.73

-9.39

-1.02

Regenetp Quarterly Data
	Apr18	Jul18	Oct18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
EBIT per Share	Get a 7-Day Free Trial															-1.05	-0.01	-0.47	-0.08	-0.65

Regenetp EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Regenetp's EBIT per Share for the fiscal year that ended in Dec. 2022 is calculated as

	EBIT per Share		(A: Dec. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-7.822	/	7.665
=	-1.02

Regenetp's EBIT per Share for the quarter that ended in Mar. 2023 is calculated as

	EBIT per Share		(Q: Mar. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-4.746	/	7.321
=	-0.65

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.21

Regenetp (OTCPK:RGTPQ) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Regenetp EBIT per Share Related Terms

Thank you for viewing the detailed overview of Regenetp's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Regenetp (Regenetp) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenetp Inc (OTCPK:RGTPQ) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

1960 South 4250 West, Salt Lake City, UT, USA, 84104

Website

https://www.polarityte.com

Regenetp Inc Formerly PolarityTE Inc is a clinical-stage biotechnology company developing regenerative tissue products and biomaterials. It's focused on transforming the lives of patients by discovering, designing, and developing regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences. Its product includes SkinTE used for repair, reconstruction, replacement, or regeneration of the skin in patients who have or require treatment of acute and chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. It operates in two segments: the regenerative medicine business segment and the contract research segment.

Executives

Peter A Cohen	director	40 WEST 57TH STREET, SUITE 2020, NEW YORK NY 10019
David B Seaburg	director	1960 S 4250 W, SALT LAKE CITY UT 84104
Richard Hague	officer: Chief Operating Officer	1960 S 4250 W, SALT LAKE CITY UT 84104
Cameron J. Hoyler	other: General Counsel	1960 S 4250 W, SALT LAKE CITY UT 84104
Jeffrey Hansen Dyer	director	4041-T HADLEY ROAD, SOUTH PLAINFIELD NJ 07080
Jessica Xiaolin Shen	director	POLARITYTE, INC. (NASDAQ: PTE), 1960 S. 4250 WEST, SALT LAKE CITY UT 84104
Chris Nolet	director	C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Paul Elliot Mann	officer: Chief Financial Officer	C/O ASP ISOTOPES INC., 433 PLAZA REAL, SUITE 275, BOCA RATON FL 33432
Jacob Alexander Patterson	officer: Chief Financial Officer	14822 S. ROSESCAPE CIRCLE, HERRIMAN UT 84096
Denver Lough	10 percent owner, other: Prior D&O within 90 days	4041-T HADLEY ROAD, SOUTH PLAINFIELD NJ 07080
Rainer M Erdtmann	director	1073 ARLINGTON BLVD., EL CERRITO CA 94530
Edward Winslow Swanson	director, officer: Chief Operating Officer	181 DANTE AVE., TUCKAHOE NY 07070
Steve Gorlin	director	150 GULF SHORE DRIVE, UNIT 601, DESTIN FL 32541
Minnie Baylor-henry	director	C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803
Willie C Bogan	director	1943, ROSECREST DRIVE, OAKLAND CA 94602